Le Lézard
Classified in: Health, Science and technology
Subjects: CCA, FVT

Movano Health to Report Fourth Quarter 2023 Financial Results on Thursday, April 4, 2024


Conference Call at 2:00 PM PT/ 5:00 PM ET

PLEASANTON, Calif., April 2, 2024 /PRNewswire/ -- Movano Health (Nasdaq: MOVE), a pioneer in health technology, today announced that it will report fourth quarter 2023 financial and operating results on Thursday, April 4, 2024, after the market close. Management will host a conference call and live audio webcast to discuss these results and provide a business update on the same day at 2:00 pm PT/5:00 pm ET.

Attendees can access the live webcast here or on the investors section of Movano Health's website at https://ir.movano.com. The conference call can be accessed by dialing 1-877-407-0989 (domestic), or 1 201-389-0921 (international). Attendees can also use the Call Me Link, in which they will be dialed in to the conference call instantly on the number provided with no hold time. An archived webcast will be available on Movano Health's website approximately one hour after the completion of the event and for two years thereafter.

About Movano Health 
Founded in 2018, Movano Inc. (Nasdaq: MOVE) dba Movano Health is developing a suite of purpose-driven healthcare solutions to bring medical-grade, high-quality data to the forefront of consumer health devices. Featuring modern form factors, Movano Health's devices capture a comprehensive picture of a person's vital health information and uniquely translate the data into personalized and intelligent insights that empower consumers to live healthier and more balanced lives. Movano Health's end-to-end solutions will soon enable consumers and their healthcare professionals to utilize daily medical-grade data as a tool to proactively monitor and manage health outcomes. For more information on Movano Health, visit https://movanohealth.com/.

SOURCE Movano


These press releases may also interest you

at 05:45
Class Action Filed Against bluebird bio, Inc. (BLUE) - May 28, 2024 Deadline to Join - Contact The Gross Law Firm
The Gross Law Firm issues the following notice to shareholders of bluebird bio, Inc. . Shareholders who purchased shares of BLUE...

at 05:44
Pharmacy Automation: Revolutionizing Healthcare with Cutting-Edge Solutions
According to the latest BCC Research study, the demand for Pharmacy Automation: Technologies and Global Markets is growing from $7.8 billion in 2023 to $12.7 billion by the end of 2028, at a compound annual growth rate (CAGR) of 10.2% from 2023...

at 05:05
Sun Nuclear Showcases New Quality Management Solutions for Radiation Therapy Teams and Workflows at ESTRO Annual Meeting
Sun Nuclear, a Mirion Medical company, will feature new and enhanced solutions for better Quality Management at the ESTRO Annual Meeting, May 3-6, in Glasgow, Scotland. The Sun Nuclear booth (#930) will highlight demonstrations and insights on the...

at 04:32
Charting the Rise: MRI Technologies Soar with a 6.4% CAGR (2023-2028)
According to the latest BCC...

at 03:05
Solid Start to the Year: LEO Pharma Delivers 13% Revenue Growth Driven by Strong Performance in Dermatology
In Q1 2024, LEO Pharma delivered a revenue growth of 13% in constant exchange rates (CER). The dermatology portfolio saw accelerated growth in revenue of 16%. The acquisition of TMB-001 to the treatment of congenital ichthyosis added a late-stage...

at 02:22
Hansa Biopharma: increase in number of shares and votes
Hansa Biopharma AB (publ), ("Hansa" or the "Company") (STO: HNSA) today announced that the company's registered share capital and number of shares and votes have increased through the issue of 10,474,740 new ordinary shares on 12 April 2024, whereby...

More news about Health...


News published on and distributed by: